Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
2.251
Zitationen
5
Autoren
2020
Jahr
Abstract
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
Ähnliche Arbeiten
Wolbachia: master manipulators of invertebrate biology
2008 · 2.867 Zit.
Pharmacokinetics of a novel formulation of ivermectin after administration to goats
2006 · 1.781 Zit.
Helminth infections: the great neglected tropical diseases
2008 · 1.575 Zit.
Control of Neglected Tropical Diseases
2007 · 1.568 Zit.
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
2002 · 1.382 Zit.